Alopecia Areata Clinical Trials

29 recruiting

Alopecia Areata Trials at a Glance

33 actively recruiting trials for alopecia areata are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Miami, New York, and San Antonio. Lead sponsors running alopecia areata studies include Pfizer, AbbVie, and CorEvitas.

Browse alopecia areata trials by phase

Treatments under study

About Alopecia Areata Clinical Trials

Looking for clinical trials for Alopecia Areata? There are currently 29 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Alopecia Areata trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Alopecia Areata clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 33 trials

Recruiting

Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

Alopecia Areata
Pfizer300 enrolled1 locationNCT07226531
Recruiting
Phase 3

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Severe Alopecia Areata
Pfizer140 enrolled41 locationsNCT07029828
Recruiting
Phase 1

Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

HealthySevere Alopecia AreataActive Non-segmental Vitiligo
Innovent Biologics (Suzhou) Co. Ltd.160 enrolled1 locationNCT07554222
Recruiting
Phase 2

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

Alopecia Areata
Eli Lilly and Company60 enrolled29 locationsNCT07533006
Recruiting
Phase 3

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Alopecia Areata
AbbVie1,500 enrolled268 locationsNCT06012240
Recruiting
Phase 2

Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

Alopecia Areata
NEXTGEN Bioscience73 enrolled2 locationsNCT06104839
Recruiting
Phase 3

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

Severe Alopecia Areata
Pfizer225 enrolled80 locationsNCT07029711
Recruiting
Phase 1Phase 2

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Alopecia Areata (AA)
Aldena Therapeutics24 enrolled7 locationsNCT06826196
Recruiting
Phase 2

Dupilumab in the Treatment of Pediatric Alopecia Areata

Alopecia Areata
Icahn School of Medicine at Mount Sinai76 enrolled5 locationsNCT05866562
Recruiting

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

Alopecia Areata
Pfizer850 enrolled58 locationsNCT06531109
Recruiting

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

Alopecia AreataHidradenitis SuppurativaNon-Segmental Vitiligo (NSV)
AbbVie2,795 enrolled116 locationsNCT07136467
Recruiting

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Alopecia Areata
CorEvitas1,500 enrolled1 locationNCT06562270
Recruiting

CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry

Alopecia Areata
CorEvitas5,000 enrolled1 locationNCT05745389
Recruiting
Not Applicable

PALLAS Laser for Skin Diseases

Alopecia AreataAtopic DermatitisPsoriasis+1 more
Szeged University50 enrolled1 locationNCT07250997
Recruiting
Phase 2

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

Alopecia AreataAtopic Dermatitis
Icahn School of Medicine at Mount Sinai56 enrolled1 locationNCT07242638
Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Alopecia Areata
Sun Pharmaceutical Industries, Inc.355 enrolled64 locationsNCT07133308
Recruiting
Not Applicable

Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata

Alopecia Areata
Zagazig University88 enrolled1 locationNCT06327581
Recruiting
Phase 2

A Study of LAD603 in Adults With Alopecia Areata

Alopecia Areata
Almirall, S.A.136 enrolled1 locationNCT07311564
Recruiting
Phase 3

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

Alopecia Areata
AbbVie123 enrolled15 locationsNCT07023302
Recruiting
Phase 1

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

Alopecia AreataVitiligo
Dren Bio80 enrolled20 locationsNCT06602232